Clinical trials: Muscle Invasive Bladder Cancer
Bladder Cancer
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.
- Trial name
- OU-SCC-ABC (NCT03892642)
- Testing
- Avelumab, BCG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Oklahoma
Muscle Invasive Bladder Cancer
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive…
- Trial name
- TEP-Vessie (NCT04053101)
- Testing
- PET CT
- Where
- 2 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut Bergonié
Urinary Bladder Neoplasms
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
- Trial name
- CheckMate 9UT (NCT03519256)
- Testing
- Nivolumab, BCG, BMS-986205
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01410565
- Testing
- Apaziquone
- Where
- 47 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Muscle-invasive Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are…
- Trial name
- IMvigor011 (NCT04660344)
- Testing
- Atezolizumab, Signatera
- Where
- 141 sites in United States, Argentina and 21 more
- Volunteers
- 761 people
- Sponsor
- Hoffmann-La Roche
Superficial Bladder Cancer
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC.
- Trial name
- NCT02773849
- Testing
- ADSTILADRIN
- Where
- 34 sites in United States
- Volunteers
- 157 people
- Sponsor
- Ferring Pharmaceuticals
Bladder Cancer, Urinary Bladder
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and cisplatin) plus this new targeted pill (sunitinib) can help shrink your tumor before you undergo surgery for your bladder…
- Trial name
- NCT00847015
- Testing
- Sunitinib, Gemcitabine, cisplatin
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
The purpose of this study is to investigate if blue light cystoscopy with Cysview improves detection of tumors in patients with bladder cancer during surveillance cystoscopy, using the KARL STORZ D-Light C PDD Flexible Videoscope…
- Trial name
- NCT02560584
- Testing
- Hexaminolevulinate hydrochloride, KARL STORZ D-Light C PDD Flexible Videoscope System
- Where
- 17 sites in United States
- Volunteers
- 304 people
- Sponsor
- Photocure
Bladder Cancer
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
This is a Phase 3, randomized, multicenter, multi-arm, placebo-controlled, double-blind study of apaziquone in participants with ≤4 non-muscle invasive bladder cancer (NMIBC), ≤3.5 centimeters (cm) in diameter, all of which must…
- Trial name
- NCT02563561
- Testing
- Apaziquone
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Non-muscle Invasive Bladder Cancer (NMIBC)
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
A parallel group, open label, multi-centre, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in recurrent intermediate risk NMIBC.
- Trial name
- PemBla (NCT03167151)
- Testing
- Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Oxford
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Bladder Cancer Stage II
Radiogenomics of Muscle Invasive Bladder Cancer
Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder…
- Trial name
- NCT04806334
- Testing
- MRI imaging of the pelvis/bladder, genomic analysis of tumor
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Urinary Tract Urothelial Carcinoma
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
A majority of patients with bladder cancer have disease confined to the inner lining of the bladder. Patients with high risk features (high grade tumors, tumors invading into a deeper superficial layer) are routinely treated with…
- Trial name
- Sutent (NCT00794950)
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Bladder Cancer
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.
- Trial name
- NCT00974818
- Testing
- Mitomycin C (MMC), Bacillus Calmette-Guerin (BCG)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
This study will enrol patients with maximally resected (via transurethral resection (TURBT) non-metastatic muscle invasive bladder cancer, who either wish to attempt bladder preservation therapy or are ineligible for cystectomy.
- Trial name
- PCR-MIB (NCT02662062)
- Testing
- Pembrolizumab, Cisplatin, Radiotherapy
- Where
- 7 sites in Australia
- Volunteers
- 28 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Poisoning by BCG Vaccine
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
The purpose of this study is to evaluate a possible role of intravesical Hyaluronic Acid in reducing local toxicity of Bacillus Calmette Guerin (BCG) used to treat bladder urothelial cell carcinoma.
- Trial name
- NCT02207608
- Testing
- Hyaluronic Acid, BCG (Immucist®)
- Volunteers
- 30 people
- Sponsor
- University of Rome Tor Vergata
Urinary Bladder Neoplasms
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
- Trial name
- CheckMate 7G8 (NCT04149574)
- Testing
- nivolumab, Bacillus Calmette-Guérin (BCG)
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
This is an open-label, window of opportunity platform study for subjects with muscle-invasive bladder cancer (MIBC) who are deemed ineligible or refuse cisplatin-based neoadjuvant chemotherapy and are scheduled to undergo…
- Trial name
- NCT03978624
- Testing
- Pembrolizumab, Entinostat, Procedure/Surgery
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Muscle Invasive Bladder Cancer
Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer
Currently the standard treatment of muscle invasive bladder cancer is the complete removal of bladder and adjacent organs, such as prostate or ovaries. Radical cystectomy is fraught with complications and risk of death.
- Trial name
- NCT02716896
- Testing
- Radiation and chemoradiation, Radical cystectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- The University of Texas Health Science Center at San Antonio